Tirzepatide hypothesized to modulate refractory endometriosis via multi-axis metabolic, immune, and fibrotic pathways

Endometriosis is a chronic systemic disorder characterized by ectopic endometrial-like tissue, leading to persistent pelvic pain and infertility. Current treatments, primarily surgery and hormonal therapies, often have limited efficacy and significant side effects, leaving many patients with treatment-refractory disease. The condition is increasingly understood to involve complex interactions between metabolic dysfunction, immune dysregulation, fibrosis, and nociceptive sensitization, extending beyond the classical estrogen-dependent paradigm. This framework proposes that incretin-based therapies, like tirzepatide, could address these interconnected pathological axes.

This article presents a mechanistic, translational hypothesis rather than experimental data. The authors propose a framework suggesting how tirzepatide, a dual GIP and GLP-1 receptor agonist, could modulate four interconnected pathological axes of refractory endometriosis. The hypothesis emphasizes the concept of "peritoneal incretin deficiency," characterized by reduced peritoneal GLP-1 concentrations and increased expression of incretin-degrading proteases. The proposed mechanisms converge on three molecular nodes: AMPK-associated signaling, GLP-1 receptor activity in peritoneal macrophages and spinal microglia, and the NF-κB/NLRP3/TGF-β1 axis.

The proposed framework links tirzepatide's actions to the complex pathophysiology of refractory endometriosis through three convergent molecular nodes. It suggests that tirzepatide could counteract Warburg-type metabolic reprogramming and lactate accumulation, which are characteristic of endometriotic lesions. Furthermore, it posits that tirzepatide may modulate peritoneal immune dysfunction, specifically targeting GLP-1 receptor activity in peritoneal macrophages and spinal microglia to reduce inflammation. The hypothesis also details how tirzepatide could impact NF-κB/NLRP3/TGF-β1-driven inflammatory-fibrotic remodeling, a key driver of lesion persistence.

Finally, the framework proposes that tirzepatide could alleviate persistent nociceptive sensitization, thereby addressing the severe pelvic pain associated with the condition. This multi-axis modulation is theorized to occur via AMPK activation, direct GLP-1 receptor signaling, and inhibition of the NF-κB/NLRP3/TGF-β1 inflammatory-fibrotic cascade.